{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-016146","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.738779+00:00","generated_at":"2026-06-08T06:17:36.360910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA","bullets":["Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.","Total revenues decreased 92% to $1.3M in Q3 2023 from $16.6M in Q3 2022, largely from prior-year non-cash collaboration revenue.","Loss from continuing operations $19.8M ($0.08 per share) vs. $7.6M ($0.04) in Q3 2022.","FDA agreed ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as pivotal for accelerated BLA; Phase 2 enrollment complete, expected completion Q2 2024.","SG&A costs down 9% in Q3 and 17% for first nine months 2023 vs. prior year, driven by reduced professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-016146","json":"https://secwatch.observer/filing/0000950103-23-016146.json","markdown":"https://secwatch.observer/filing/0000950103-23-016146.md","text":"https://secwatch.observer/filing/0000950103-23-016146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/0000950103-23-016146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/dp202678_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:17:36.360910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"049e401181c07a693ec3b9922d36e6ee2bf0be42","claim":"PRECIGEN, INC. reported financial results for third quarter 2023.","evidence_excerpt":"Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/0000950103-23-016146-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}